FDA Inspection
Bioreliance CorporationBioreliance Corporation – FDA Inspection, Aug 4, 2023
Record Details
This FDA Inspection record concerns Bioreliance Corporation, with an inspection on August 4, 2023, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 89149f6b-0201-4f3c-9500-60de669dfba4
Inspection Facts
No Action Indicated (NAI)
No objectionable conditions or practices were found during the inspection.
- Inspection number
- 1215040
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of Bioreliance Corporation
11| Date | Classification | Office | Project area |
|---|---|---|---|
| January 29, 2026 | VAI | Baltimore District Office | Bioresearch Monitoring: Human Drugs |
| November 22, 2024 | VAI | Baltimore District Office | Vaccine, Allergenic, and Live Biotherapeutic Products |
| August 8, 2019 | Not classified | Baltimore District Office | |
| July 13, 2018 | VAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| January 11, 2016 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Bioreliance Corporation
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.